Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer Sells 15,000 Shares

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 15,000 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $1.25, for a total transaction of $18,750.00. Following the completion of the transaction, the chief operating officer now owns 135,246 shares in the company, valued at $169,057.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Equillium Trading Down 3.6 %

Shares of NASDAQ:EQ opened at $0.83 on Friday. Equillium, Inc. has a twelve month low of $0.45 and a twelve month high of $3.25. The firm has a market cap of $29.40 million, a P/E ratio of -3.32 and a beta of 1.83. The company has a 50 day moving average of $0.96 and a 200-day moving average of $1.04.

Equillium (NASDAQ:EQ) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.16. The firm had revenue of $13.85 million for the quarter, compared to analyst estimates of $8.15 million. Equillium had a negative net margin of 19.51% and a negative return on equity of 36.88%. Equities research analysts forecast that Equillium, Inc. will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC increased its position in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 300,400 shares of the company’s stock after buying an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned 0.85% of Equillium worth $208,000 at the end of the most recent quarter. 27.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Equillium in a research note on Monday, August 19th.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.